Screened 2026-09-15 · the tape above runs as of 05:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
AvePoint, Inc. holds its Markup at $13.60. The statistical read favours the sellers, held for 19 days.
As held on the ledger · 2026-09-15
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 19 days
Price at the screen
$13.60
Valuation
43.85 trailing · 27.43 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.19
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
1.26%
Below 33%
Interest-bearing debt is just 1.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
73.39%
Below 49%
Money owed to the company is 73.4% of assets, above the 49% limit.
Fail
Revenue purity
1.09%
Below 5%
Only 1.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-15 screen. The gold marker is the market price at the same screen. A 2.6% margin of safety to the base estimate.
Third-party analyst targets: 13 covering, consensus None. The average target sits +10% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-15 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Cloud data tools rarely clear a fair price
Picture a company whose software organises the endless files that pile up inside Microsoft 365 and SharePoint. AvePoint does that job, yet it trades at 26.6 times forward earnings for 26 percent revenue growth and an 11 percent profit margin. With the shares only 6 percent below our fair value, the margin of safety is wafer thin and the opportunity rating sits at none.
The numbers show steady progress, a 12 percent return on equity and an ethical screen that passes cleanly, but the valuation already prices in the growth analysts expect. Thirteen firms carry a buy rating and a 15 dollar median target; nothing here suggests the market has overlooked a bargain.
High multiples leave little room for the usual software hiccups of slower renewals or rising competition. When growth cools even a notch the rating can compress quickly. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AVPT trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-22Markup$12.79-3.3%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it none, with a mean price target of $16.
2026-07-22Markup$13.22+21.6%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 21.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it none, with a mean price target of $16.
2026-07-18Markup$10.87+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it none, with a mean price target of $16.
2026-07-03Markup$10.87+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$10.87Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
